论文部分内容阅读
目的探讨ICU革兰阳性球菌感染给予利奈唑胺治疗的临床疗效和安全性。方法选取ICU革兰阳性球菌感染患者124例作为研究对象,根据随机数字表法分为研究组和对照组,每组62例。研究组给予利奈唑胺治疗,对照组给予万古霉素治疗,观察两组患者的临床疗效及不良反应发生率,并进行统计学分析。结果治疗后,研究组总有效58例,总有效率为93.55%,对照组总有效50例,总有效率为80.65%,差异有统计学意义(P<0.05);研究组发生不良反应2例,不良反应发生率为3.24%,对照组发生不良反应7例,不良反应发生率为11.29%,差异有统计学意义(P<0.05)。结论利奈唑胺可有效控制革兰阳性球菌感染患者,提升临床治疗疗效,且治疗过程中安全性较高,值得临床推广应用。
Objective To investigate the clinical efficacy and safety of linezolid in patients with ICU infection. Methods 124 cases of gram-positive cocci infection in ICU were selected as research objects, divided into study group and control group according to random number table method, with 62 cases in each group. The study group was given linezolid and the control group was given vancomycin. The clinical efficacy and the incidence of adverse reactions in the two groups were observed and statistically analyzed. Results After treatment, the total effective rate of study group was 58, the total effective rate was 93.55%, the total effective rate was 50.6% in control group, the total effective rate was 80.65%, the difference was statistically significant (P <0.05); adverse reactions occurred in 2 cases , The incidence of adverse reactions was 3.24%, 7 cases of adverse reactions in the control group, the incidence of adverse reactions was 11.29%, the difference was statistically significant (P <0.05). Conclusion Linezolid can effectively control Gram-positive cocci infection in patients with clinical efficacy and enhance the safety of treatment is worthy of clinical promotion and application.